Download Free Medical IMAGING IN BREAST CANCER PowerPoint Presentation

IMAGING IN BREAST CANCER PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Radiology and Imaging, which is titled "IMAGING IN BREAST CANCER", to know about imaging in the case of breast cancer.

Tags : Radiology, Imaging, breast cancer

Published on : Aug 02, 2021 | Views : 2726 | Downloads : 9

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Dr Deepika Malik J.R. II Department of Radiotherapy
Slide 2-

Imaging modalities in breast cancer are used for screening as well as diagnosis. -Mammography -Ultrasonography - MRI scan -CT scan -PET scan -Bone scan
Slide 3-

Mammography  Is used both as a screening as well as diagnostic tool in breast cancer
Slide 4-

Screening Mammogram Before 1977, no formal guidelines existed for screening women for occult breast cancer. The publication of the Health Insurance Plan (HIP) of Greater New York Screening Project, in the 1960s, led the National Cancer Institute and the American Cancer Society to support a breast cancer screening project to evaluate further the efficacy of screening by mammography and physical examination.
Slide 5-

At 5 years, the HIP study found a 50% decrease in mortality rate in women older than 50 years of age, but only a 5% decrease in mortality rate in women younger than 50 years of age. With follow-up, the mortality rate in women younger than 50 years of age showed a 23.5% Women who refused screening had no reduction in mortality rate.
Slide 6-

 Screening Mammogram Although an active area of debate Several authors agree that screening mammography in women 40-49 years of age may reduce mortality from breast cancer Health insurance plan study, (1963-1969)  Taber et al (1988-1996) {Canadian study- addition of annual mammography screening had no effect on breast cancer mortality}
Slide 7-

National Organizations' Screening Guidelines for Mammography ACS (American college of surgeons) For women for normal risk, yearly mammograms are recommended starting at age 40. CBE suggested about every three years for women in the 30′s and every year for women age 40 and above. BSE is suggested for women starting in their 20s.
Slide 8-

NCCN Women at normal risk are recommended to have CBE every 1–3 years; periodic SBE is encouraged. Beginning at age 40, annual CBE and mammograms are recommended, and periodic SBE is encouraged.
Slide 9-

NCI Women who are age 40 and above should be screened with mammograms every 1–2 years.
Slide 10-

For age group <50 years The National Cancer Institute, American Cancer Society, and the American College of Radiology recommend a baseline mammogram at the age of 35 years (30 years in high-risk groups). Repeat examinations should be carried out every 2 years beginning at 40 years of age. In women older than 50 years, mammograms should be performed annually. Frisell J, Lidbrink E. The Stockholm Mammographic Screening Trial: risks and benefits in age group 40-49 years. J Natl Cancer Inst Monogr 1997:49â€“51. UK Trial Group. 16-year mortality from breast cancer in the UK trial of early detection of breast cancer. Lancet 1999;353:1909â€“1914 Kerlikowske K, Grady D, Rubin SM, et al. Efficacy of screening mammography. A meta-analysis. JAMA 1995;273:149â€“154. Feig SA. Estimation of currently attainable benefit from mammographic screening of women aged 40-49 years. Cancer 1995;75:2412â€“2419
Slide 11-

Diagnostic mammogram most critical component of diagnostic imaging in breast cancer patients bilateral mammograms should be performed routinely in the work-up of the breast cancer patient
Slide 12-

Special x-ray machines developed exclusively for breast imaging produce mammography films. use very low doses of radiation and produce high-quality x-rays
Slide 13-

 The patient wears an open wrap and undress above the waist
Slide 14-

 Breast is briefly compressed between 2 plates attached to the mammogram machine– an adjustable plastic plate on top and a fixed plate on bottom which holds the x-ray film
Slide 15-

 We should be familiar with the difference between diagnostic and screening mammogram.  Screening mammogram- Routine mammogram, done in asymptomatic women 2 views- craniocaudal, mediolateral
Slide 16-

 Diagnostic mammogram- To characterise abnormalities detected at screening or in women with palpable masses Additional magnification views Done in presence of radiologist generally to determine need for additional views or follow up studies -lateromedial(from side towards center of chest) mediolateral(from the center of the chest out) Spot compression view
Slide 17-

ppt slide no 17 content not found
Slide 18-

ppt slide no 18 content not found
Slide 19-

ppt slide no 19 content not found
Slide 20-

Mammographic abnormalities Mammographic signs of cancer consist of two primary findings: (1) a mass with ill-defined, irregular, or spiculated edges and/or (2) irregular, pleomorphic calcifications
Slide 21-

Benign cyst of breast
Slide 22-

IDC- mass with illdefined , spiculated margins Benign masses- well defined, with sharp margins, and have little effect on the surrounding breast architecture
Slide 23-

Calcifications Could be associated with benign or malignant conditions of breast
Slide 24-

Typical popcorn calcification FIBROADENOMA
Slide 25-

 In malignant tumors– calcification 100 to 300 micrometeres, rod like , tubular, branching, punctate
Slide 26-

Vascular calcifications These are linear or form parallel tracks, that are usually clearly associated with blood vessels.
Slide 27-

Micro-calcifications can be very subtle Biopsy of this area showed 8mm DCIS
Slide 28-

Biopsy = DCIS with focal micro-invasion
Slide 29-

In ductal carcinoma in situ (DCIS), there is normally no mass but just an area of calcification
Slide 30-

CC and MLO mammographic views show a large and relatively circumscribed ovalar lesion in the upper outer quadrant. On US scan it consists on a complex cyst with a parietal ill-defined mass (arrows). US-guided core needle biopsy of the intracystic mass revealed a malignant phyllodes tumor
Slide 31-

 The BIRADS ( Breast Imaging and Reporting Data System) classification system is widely adopted in classifying mammograms with respect to appropraite follow up and intervention
Slide 32-

Nothing to comment on. Breasts are symmetric ; no masses, architectural disturbances, or suspect calcifications are present. Category 1 Negative
Slide 33-

 Negative mammogram, but the interpreter may wish to describe a finding. Involuting, calcified fibroadenomas, multiple secretory calcifications, fat- containing lesions such as oil cysts, lipomas, galactoceles, and mixed-density hamartomas all have characteristic appearances, and may be labeled with confidence.  The interpreter might wish to describe intramammary lymph nodes, implants, and the like, while still concluding that there is no mammographic evidence of malignancy Category 2 Benign finding
Slide 34-

 A finding placed in this category should have a very high probability of being benign  Not expected to change over the follow-up interval, but the radiologist would prefer to establish its stability. (Data are becoming available that shed light on the efficacy of short-interval follow-up. At present, most approaches are intuitive. These will likely undergo future modification as more data accrue as to the validity of an approach) Category 3 Probably benign finding ---short-interval follow-up suggested
Slide 35-

 lesions that do not have the characteristic morphologies of breast cancer but have a definite probability of being malignant.  The radiologist has concern to urge a biopsy. Category 4 Suspicious abnormality-- ----biopsy should be considered
Slide 36-

 These lesions have a high probability of being cancer Category 5 Highly suggestive of malignancy----appropriate action should be taken
Slide 37-

Finding for which additional imaging evaluation is needed. almost always used in a screening situation and should rarely be used after a full imaging workup.  Perez , 6th edition , pg-1058 Category 0 Need additional imaging evaluation
Slide 38-

Ultrasonography Complementary tool to mammography for diagnosis and screening of breast cancer Cannot replace mammography
Slide 39-

 Screening USG In a randomised trial of USG and Mammography of 2809 women with dense breasts from ACRIN, Adding a single screening USG yielded and additional 1.1 to 7.2 additional cancers found in high risk women\ But a substantial increase in false positives Role of USG as a screening tool is therefore limited
Slide 40-

Diagnostic USG  But is a useful tool to complement physical examination and mammography in diagnosis and treatment of cancer. Sensitivity of 73% specificity of 95%
Slide 41-

 USG Breast is most useful in differentiating cysts from solid tumors Identification and characterisation of palpable and non palpable abnormalities of breast detected by physical examination or mammography.
Slide 42-

USG breast--- very accurate (>95%) in diagnosing breast cysts. Cysts have well-demarcated, smooth margins and an echo-free center ; usually rounded and thin- walled and produce distal shadowing. Clear cysts require no further evaluation. Complex cysts that contain evidence of tissue or debris may be aspirated to clarify whether they are simply cysts or represent cystic degeneration of a tumor.
Slide 43-

 USG as a guide in core biopsies FNA Cyst aspirations Presurgical localizations
Slide 44-

NCCN recommends- USG breast for patients with a dominant mass assymetric thickening nodularity
Slide 45-

MRI As supplemental tool for screening and diagnosis of breast cancer.
Slide 46-

Screening MRI Role of MRI screening is rapidly evolving But unlikely to replace mammography
Slide 47-

Its use in screening high risk populations has recently been supported in several studies. Lehman et al ( MRI detected 4 contralateral breast {MMG – none} cancers in 103 women with unilteral breast cancer) Kriege et al ( MRI is more sensitive than mammography in detecting tumors in women at high risk for familial breast cancer)
Slide 48-

Diagnostic MRI Routine use is controversial Use to supplement mammography in breast cancer diagnosis is rapidly increasing.
Slide 49-

 Upponi and Warren – MRI resulted in an increase in confidence or change in clinical plan in 46% of diagnostic group, 72 % of chemotherapy group, 80 % of screening group. In 44/283 of these MRI resulted in a beneficial change in plan. Esserman etal – MRI detected cancer in 55/58 cases; anatomic extent was correctly identified in 98% ,(MMG-55%)
Slide 50-

In a woman with dense breasts, the mammogram was normal but the MRI showed the cancer
Slide 51-

NCCN recommends Breast MRI for women with With early stage disease whose breasts cannot be imaged adequately with mammography and ultrasound Who receive NACT in occult breast cancer to assess response With genetic mutations leading to a higher risk of bilateral or contralateral breast cancer
Slide 52-

Role of MRI in Occult Breast Cancer MRI has a clear role in evaluation of patients with axillary metastasis with no evidence of primary tumor in breast by physical examination or mammography.  Buchanan et al – breast MRI detects mammographically occult cancer in half of women with axillary metastasis and is a valuable tool for patients with occult primary breast cancer.
Slide 53-

Computed Tomography No established role for CT scans in routine staging in patients of early breast cancer Its role in initial evaluation is minimal Need of iodine contrast material to differentaiate benign from malignant lesions High radiation dose Cost per study Inability to detect small lesions
Slide 54-

 NCCN recommends an abdominopelvic CT if Abnormal lab values Positive findings on physical examination For stage IIIA ( T3N1M0 ) or greater.
Slide 55-

Bone Scan Not routinely used for initial evaluation of early stage breast cancer. Koizumi et al reviewed records from 5538 patients of breast cancer. The overall incidence of metastasis to bone was 2.13% In stage I– 0.08 % In stage II- 10.9% In stage III-9.96% In stage IV- 34.04%
Slide 56-

 Therefore bone scans are more commonly recommended in patients with Stage II large tumors (>3cm) Aggressive histopathological features Stage III or Stage IV cancer  Perez 6th edition
Slide 57-

PET scan Not a routine component of staging NCCN guidelines Recommend against routine PET scans in stage 0 to IIIA disease May be useful in patients with locally advanced disease or in situations where standard imaging results are suspicious.
Slide 58-

Schirrmeister et al --- For interpreting results as being breast cancer , FDG PET has sensitivity of 93%, specificity of 78%, accuracy of 89%, PPV 92%, NPV- 96% For detecting multifocal lesions , FDG-PET was twice as sensitive (63%) as combination of mammography and ultrasonography High false-negative rate of 20% for detection of lymph node metastases, this imaging method cannot replace histologic evaluation of axillary nodes.
Slide 59-

ppt slide no 59 content not found
Slide 60-

ppt slide no 60 content not found
Slide 61-

THANK YOU